Tumor-targeting anti-EGFR x anti-PD1 bispecific antibody inhibits EGFR-overexpressing tumor growth by combining EGFR blockade and immune activation with direct tumor cell killing

We developed a strategy to combine conventional targeted therapy with immune checkpoint blockade using a tumor-targeting bispecific antibody (BsAb) to treat solid tumors. The BsAb was designed to simultaneously engage a tumor-associated antigen, epidermal growth factor receptor (EGFR), and programed...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Li, Deng, Lan, Meng, Xiaoqing, Gu, Changling, Meng, Li, Li, Kai, Zhang, Xuesai, Meng, Yun, Xu, Wei, Zhao, Le, Chen, Jianhe, Zhu, Zhenping, Huang, Haomin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2020
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7585148/
https://www.ncbi.nlm.nih.gov/pubmed/33129108
http://dx.doi.org/10.1016/j.tranon.2020.100916

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7585148/
https://www.ncbi.nlm.nih.gov/pubmed/33129108
http://dx.doi.org/10.1016/j.tranon.2020.100916

Ejemplares similares